Search

Your search keyword '"Frassineti, Giovanni Luca"' showing total 495 results
Start Over Author "Frassineti, Giovanni Luca"
495 results on '"Frassineti, Giovanni Luca"'

1. Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Author

Rimini, Margherita, Montes, Margarida, Amadeo, Elisabeth, Vitiello, Francesco, Kudo, Masatoshi, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Lonardi, Sara, Finkelmeier, Fabian, Salani, Francesca, Antonuzzo, Lorenzo, Marra, Fabio, Iavarone, Massimo, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Sacco, Rodolfo, Rapposelli, Ilario Giovanni, Scartozzi, Mario, Nicoletta, Pella, Aldrighetti, Luca, Persano, Mara, Camera, Silvia, Rossari, Federico, Foti, Silvia, Kumada, Takashi, Hiraoka, Atsushi, Iwamoto, Hideki, Rizzato, Mario Domenico, Himmelsbach, Vera, Masi, Gianluca, Corradi, Mattia, Celsa, Ciro, Fabio, Conti, Frassineti, Giovanni Luca, Cascinu, Stefano, Casadei-Gardini, Andrea, and Presa, Jose

Published
2024
Full Text
View/download PDF

2. Prophylaxis and treatment of peritoneal carcinomatosis of gastric origin using hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis of randomized trials

Author

Stefano, Mauro, Perrina, Daniele, Vallicelli, Carlo, Ansaloni, Luca, Fugazzola, Paola, Coccolini, Federico, Agnoletti, Vanni, Frassineti, Giovanni Luca, Passardi, Alessandro, Tamberi, Stefano, Framarini, Massimo, Tassinari, Davide, Matteucci, Laura, Sturaro, Chiara, Gallo, Graziana, and Catena, Fausto

Published
2024
Full Text
View/download PDF

4. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Author

Azevedo, Sergio, Braghiroli, Maria Ignez, Girotto, Gustavo, Bragagnoli, Arinilda, Branco, Ricardo, Faccio, Adilson, Moretto, Andrea, Skare, Nils, Dutra, Jamille, Viola, Luciana, Vianna, Karina, Meton, Fernando, Sette, Claudia, Faulhaber, Amanda, Tam, Vincent C., Couture, Felix, Biagi, Jim, Castel, Helene, Mulder, Karen, Ko, Yoo-Joung, Zbuk, Kevin, Welch, Stephen, Beaudoin, Annie, Heurgué, Alexandra, Assenat, Eric, Archambeaud, Isabelle, Tougeron, David, Peron, Jean-Marie, Gilabert, Marine, Bronowicki, Jean-Pierre, Cattan, Stephane, Blanc, Jean-Frederic, Bouattour, Mohamed, Phelip, Jean-Marc, Boige, Valerie, Michel, Pierre, Frin, Anne-Claire, De Toni, Enrico N., Berres, Marie-Luise, Vogel, Arndt, Berg, Thomas, Ettrich, Thomas, Waldschmidt, Dirk, Wedemeyer, Hans Heinrich, Worns, Marcus-Alexander, Bitzer, Michael, Weiss, Karl-Heinz, Lau, George, Chan, Stephen L., Yau, Thomas, Tai, Yin Ping, Lee, Ann Shing, Thungappa, Satheesh Chiradoni, N, Lokesh K., Sureshchand Ostwal, Vikas, Ashok, Kattimani Kiran, Mittal, Sushant, Goyal, Hari, Srinivasan, Sankar, Biswas, Ghanashyam, Mohan, Mallavarapu, Limaye, Sewanti, Asarawala, Nirav, Rimassa, Lorenza, Falcone, Alfredo, Gianni, Luca, Gasbarrini, Antonio, Daniele, Bruno, Avallone, Antonio, Paolo Frassineti, Giovanni Luca, Roila, Fausto, Kudo, Masatoshi, Kawaoka, Tomokazu, Morimoto, Manabu, Takikawa, Yasuhiro, Kato, Naoya, Yamashita, Tatsuya, Osaki, Yukio, Motomura, Kenta, Tateishi, Ryosuke, Ohkawa, Kazuyoshi, Wada, Yoshiyuki, Onishi, Hideki, Sasahira, Naoki, Inaba, Yoshitaka, Kurosaki, Masayuki, Tsuji, Kunihiko, Takei, Yoshiyuki, Aramaki, Takeshi, Hagihara, Atsushi, Furuse, Junji, Kioka, Kiyohide, Koga, Hironori, Sasaki, Yutaka, Numata, Kazushi, Tada, Toshifumi, Kawaguchi, Yasunori, Nadano, Seijin, Vasilyev, Alexander, Breder, Valery, Lipatov, Oleg, Dvorkin, Mikhail, Zarubenkov, Oleg, Kutukova, Svetlana, Ponomarev, Roman, Shostka, Kirill, Alyasova, Anna, Topuzov, Eldar, Severtsev, Alexey, Petrov, Yuryi, Erygin, Dmitriy, Berdov, Boris, Kang, Yoon-Koo, Tak, Won-Young, Park, Joong-Won, Lim, Ho Yeong, Heo, Jeong, Kim, Jee Hyun, Kim, Tae-You, Choi, Hye Jin, Varela, María, Reig Monzon, María Elisa, Sangro, Bruno, Martin, Carlos Gómez, Ponce, Carmen Guillén, López, Carlos, Cheng, Ann-Lii, Chao, Yee, Feng, Yin-Hsun, Jeng, Long-Bin, Hung, Chao-Hung, Hou, Ming-Mo, Wang Tsang-En Wang, Jing-Houng, Yen, Chia-Jui, Sukeepaisarnjaroen, Wattana, Sunpaweravong, Patrapim, Charoentum, Chaiyut, Tanasanvimon, Suebpong, Sirachainan, Ekaphop, Ungtrakul, Teerapat, Prasongsook, Naiyarat, Maneenil, Kunlatida, Jitpewngarm, Wittawat, Ostapenko, Yurii, Skoryi, Denys, Bondarenko, Igor, Shparyk, Yaroslav, Trukhin, Dmytro, Hotko, Yevhen, Ursol, Grygorii, Kryzhanivska, Anna, Abou-Alfa, Ghassan K., Mody, Kabir, Dayyani, Farshid, Al-Rajabi, Raed, Yarchoan, Mark, Gandhi, Sunil, Crysler, Oxana, He, Aiwu Ruth, Reeves, James, Bahary, Nathan, Mahipal, Amit, Kelley, Robin Kate, Dasgupta, Anirudha, Rowe, Julie, Thota, Ramya, Beg, Muhammad, Morse, Michael, Choi, Sung-hee, Crocenzi, Todd, Somer, Bradley, Abrams, Thomas, Denlinger, Crystal, Zhang, Yue, Sharma, Nisha, Dao, Tu V., Thinh, Nguyen Tien, Tuyet Phuong, Le Thi, Sangro, B., Chan, S.L., Kelley, R.K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E.N., Furuse, J., Kang, Y.K., Galle, P.R., Rimassa, L., Heurgué, A., Tam, V.C., Van Dao, T., Thungappa, S.C., Breder, V., Ostapenko, Y., Reig, M., Makowsky, M., Paskow, M.J., Gupta, C., Kurland, J.F., Negro, A., and Abou-Alfa, G.K.

Published
2024
Full Text
View/download PDF

5. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV

Author

Pietrantonio, Filippo, Bergamo, Francesca, Rossini, Daniele, Ghelardi, Filippo, De Grandis, Maria Caterina, Germani, Marco Maria, Barsotti, Giulia, Formica, Vincenzo, Frassineti, Giovanni Luca, Boscolo, Giorgia, Cinieri, Saverio, Di Donato, Samantha, Antonuzzo, Lorenzo, Antoniotti, Carlotta, Ambrosini, Margherita, Piva, Vittoria Matilde, Nichetti, Federico, Fassan, Matteo, Cremolini, Chiara, and Lonardi, Sara

Published
2023
Full Text
View/download PDF

8. Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer

Author

Urbini, Milena, Marisi, Giorgia, Azzali, Irene, Bartolini, Giulia, Chiadini, Elisa, Capelli, Laura, Tedaldi, Gianluca, Angeli, Davide, Canale, Matteo, Molinari, Chiara, Rebuzzi, Francesca, Virga, Alessandra, Prochowski Iamurri, Andrea, Matteucci, Laura, Sullo, Francesco Giulio, Debonis, Silvia Angela, Gallio, Chiara, Frassineti, Giovanni Luca, Martinelli, Giovanni, Ulivi, Paola, and Passardi, Alessandro

Published
2023
Full Text
View/download PDF

9. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Author

Reni, Michele, Macchini, Marina, Orsi, Giulia, Peretti, Umberto, Valente, Mariamaddalena, Giommoni, Elisa, Antonuzzo, Lorenzo, Di Costanzo, Francesco, Bergamo, Francesca, Zagonel, Vittorina, Lonardi, Sara, Buggin, Federica, Milella, Michele, Palmerio, Silvia, Cavanna, Luigi, Di Nunzio, Camilla, Di Marco, Maria Cristina, Grassi, Elisa, Spada, Massimiliano, Messina, Marco, Cordio, Stefano, Avola, Francesco, Aprile, Giuseppe, Pagano, Salvatore, Simionato, Francesca, Cardellino, Giovanni Gerardo, Majer, Federica, Maiello, Evaristo, Latiano, Tiziana Pia, Chiarazzo, Cinzia, Artioli, Fabrizio, Razzini, Giorgia, Pasqualini, Antonella, Ghidini, Michele, Binda, Elisa, Lazzarelli, Silvia, Bozzarelli, Silvia, Sala, Simona, Luppi, Gabriele, Pettorelli, Elisa, Spallanzani, Andrea, Vicario, Giovanni, Salmaso, Flavia, Basso, Marco, Silvestris, Nicola, Del Curatolo, Sabina, Zustovich, Fable, Bongiovanni, Francesca, Longobardi, Ciro, Sandi, Ilenia, Fontanella, Caterina, Montelatici, Silvia, Giordano, Monica, Luchena, Giovanna, Gilardoni, Micol, Tamburini, Emiliano, Rudnas, Britt, Venturini, Barbara, Merelli, Barbara, Negrini, Giorgia, Vici, Elio Maria, Marabese, Alessandra, Garetto, Cristina, Curcio, Paola, Cinieri, Saverio, Cinefra, Margherita, Ferrara, Pasqualinda, Cantore, Maurizio, Morselli, Patrizia, Fumi, Guglielmo, Isidori, Agnese, Ciccarese, Giovanni, Paolo Frassineti, Giovanni Luca, Pagan, Flavia, Vaccaro, Vanja, Spoto, Chiara, Ferrara, Marianna, Garufi, Carlo, Caporale, Marta, Vasile, Enrico, Salani, Francesca, Barone, Elisa, Berardi, Rossana, Onofri, Azzurra, Ballatore, Zelmira, Lucarelli, Alessandra, Barucca, Alessandra, Pancotti, Amedeo, Scipioni, Teresa, Bencardino, Katia, Marrapese, Giovanna, Idotta, Laura, Petrelli, Fausto, Lonati, Veronica, Ceribelli, Anna, Giuli, Angelo, Zannori, Cristina, Bassanelli, Maria, Mambrini, Andrea, Ginocchi, Laura, Orlandi, Massimo, Celio, Luigi, Niger, Monica, Biamonte, Lavinia, Tamberi, Stefano, Piancastelli, Alessandra, Papiani, Giorgio, Valli, Irene, Allione, Paolo, Boe, Maria Giovanna, Scartozzi, Mario, Lai, Eleonora, Pireddu, Annagrazia, Ziranu, Pina, Demurtas, Laura, Puzzoni, Marco, Mariani, Stefano, Pretta, Andrea, Liscia, Nicole, Savastano, Clementina, Malaspina, Valentina, Tonini, Giuseppe, Grassani, Teresa, Barco, Barbara, Pierosandro, Tagliaferri, Ciliberto, Domenico, Ierardi, Antonella, Calandruccio, Natale Daniele, Minotti, Vincenzo, Matocci, Roberta, Torri, Valter, Porcu, Luca, Rulli, Erica, De Simone, Irene, Carlucci, Luciano, Rulli, Eliana, Poli, Davide, Tonto, Paola, Scellato, Francesca, Pinto, Carmine, Reni, M., Giommoni, E., Bergamo, F., Milella, M., Cavanna, L., Di Marco, M.C., Spada, M., Cordio, S., Aprile, G., Cardellino, G.G., Maiello, E., Bernardini, I., Ghidini, M., Bozzarelli, S., Macchini, M., Orsi, G., De Simone, I., Rulli, Er., Porcu, L., Torri, V., and Pinto, C.

Published
2023
Full Text
View/download PDF

10. Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.

Author

Pietrantonio, Filippo, primary, Randon, Giovanni, additional, Lonardi, Sara, additional, Garattini, Silvio Ken, additional, Tamberi, Stefano, additional, Giommoni, Elisa, additional, Di Donato, Samantha, additional, Fornaro, Lorenzo, additional, Brunetti, Oronzo, additional, De Vita, Ferdinando, additional, Frassineti, Giovanni Luca, additional, Chini, Claudio, additional, Spallanzani, Andrea, additional, Bethaz, Valerie, additional, Strippoli, Antonia, additional, Latiano, Tiziana Pia, additional, Cardellino, Giovanni Gerardo, additional, Palermo, Federica, additional, Miceli, Rosalba, additional, and Di Bartolomeo, Maria, additional

Published
2024
Full Text
View/download PDF

12. Prostate cancer: evaluation of outcomes and prognostic factors in adjuvant and salvage radiation treatment

Author

Frassineti, Giovanni Luca Paolo, Cortesi, Annalisa <1984>, Frassineti, Giovanni Luca Paolo, and Cortesi, Annalisa <1984>

Abstract

Adjuvant radiotherapy in prostate cancer: impact of older age and hypofractionated regimens on acute and late toxicity. A multicenter comprehensive analysis Background: The objective of this study was to assess the impact of patient and treatment characteristics on toxicity in prostate cancer patients receiving adjuvant radiotherapy (RT). Materials and methods: This observational study evaluated both acute and late toxicity. Patient- (age; Charlson’s comorbidity index) and treatment-related characteristics (nodal irradiation; previous TURP; use, type, and duration of ADT, RT fractionation and technique, image-guidance systems, EQD2 delivered to prostate bed and pelvic nodes) were recorded and analyzed. Results: A total of 381 patients were enrolled. The median EQD2 to the prostate bed was 71.4 Gy. 75.4% of patients were treated with intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT). Acute G3 gastrointestinal (GI) and genitourinary (GU) toxicity rates were 0.5% and 1.3%, respectively. No patients experienced >G3 acute toxicity. The multivariable analysis of acute toxicity showed a statistically significant association between older age (> 65) and decreased odds of G≥2 GI acute toxicity (OR: 0.569; 95%CI: 0.329-0.973; p: 0.040) and decreased odds of G≥2 GU acute toxicity (OR: 0.956; 95%CI: 0.918- 0.996; p: 0.031). The 5-year late toxicity-free survival rates for G≥3 GI and GU toxicity were 98.1% and 94.5%, respectively. The only significant correlation found (Cox’s regression model) was a reduced risk of late GI toxicity in patients undergoing hypofractionation (HR: 0.38; 95% CI: 0.18-0.78; p: 0.008). Conclusions: The unexpected results of this analysis could be explained by a “response shift bias” concerning the protective effect of older age and by treatment in later periods (using IMRT/VMAT) concerning the favorable effect of hypofractionation. However, the study suggests that age should not be a reason to avoid adjuvant RT and

Published
2024

13. Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Author

Bang, Yeonghak, Yoo, Changhoon, Lonardi, Sara, Kim, Hyung-Don, Vivaldi, Caterina, Rimini, Margherita, Frassineti, Giovanni Luca, Park, Sook Ryun, Rizzato, Mario Domenico, Ryu, Min-Hee, Salani, Francesca, Rapposelli, Ilario Giovanni, Ryoo, Baek-Yeol, Zagonel, Vittorina, Massa, Valentina, Valgiusti, Martina, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2021
Full Text
View/download PDF

14. Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study.

Author

Provinciali, Nicoletta, Piccininno, Marco, Siri, Giacomo, Gennari, Alessandra, Antonucci, Giancarlo, Ricci, Damiano, Devoto, Emmanuela, Miceli, Roberta, Cortesi, Pietro, Pazzi, Chiara, Nanni, Oriana, Mannozzi, Francesca, Pastina, Ilaria, Messuti, Luciana, Bengala, Carmelo, Frassineti, Giovanni Luca, Cattrini, Carlo, Fava, Marianna, Webber, Tania Buttiron, and Briata, Irene Maria

Abstract

Background: Serum biomarkers have been investigated as predictive risk factors for cancer-related cardiovascular (CV) risk, but their analysis is limited to their baseline level rather than their overtime change. Besides historically validated causal factors, inflammatory and oxidative stress (OS) related markers seem to be correlated to CV events but this association needs to be further explored. We conducted an observational study to determine the predictive role of the longitudinal changes of commonly used and OS-related biomarkers during the cancer treatment period. Methods: Patients undergoing anticancer therapies, either aged 75+ years old or younger with an increased CV risk according to European Society of Cardiology guidelines, were enrolled. We assessed the predictive value of biomarkers for the onset of CV events at baseline and during therapy using Cox model, Subpopulation Treatment-Effect Pattern Plot (STEPP) method and repeated measures analysis of longitudinal data. Results: From April 2018 to August 2021, 182 subjects were enrolled, of whom 168 were evaluable. Twenty-eight CV events were recorded after a median follow up of 9.2 months (Interquartile range, IQR: 5.1–14.7). Fibrinogen and troponin levels were independent risk factors for CV events. Specifically, patients with higher than the median levels of fibrinogen and troponin at baseline had higher risk compared with patients with values below the medians, hazard ratio (HR) = 3.95, 95% CI, 1.25–12.45 and HR = 2.48, 0.67–9.25, respectively. STEPP analysis applied to Cox model showed that cumulative event-free survival at 18 and 24 months worsened almost linearly as median values of fibrinogen increased. Repeated measure analysis showed an increase over time of D-Dimer (p-interaction event*time = 0.08), systolic (p = 0.07) and diastolic (p = 0.05) blood pressure and a decrease of left ventricular ejection fraction (p = 0.15) for subjects who experienced a CV event. Conclusions: Higher levels of fibrinogen and troponin at baseline and an increase over time of D-Dimer and blood pressure are associated to a higher risk of CV events in patients undergoing anticancer therapies. The role of OS in fibrinogen increase and the longitudinal monitoring of D-dimer and blood pressure levels should be further assessed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Author

Falcone, Alfredo, Lonardi, Sara, De Braud, Filippo Guglielmo Maria, Bordonaro, Roberto, Maiello, Evaristo, Tamburini, Emiliano, Santini, Daniele, Frassineti, Giovanni Luca, Gamucci, Teresa, Aprile, Giuseppe, Zaniboni, Alberto, Granetto, Cristina, Buonadonna, Angela, Di Costanzo, Francesco, Tomasello, Gianluca, Gianni, Luca, Di Donato, Samantha, Carlomagno, Chiara, Clavarezza, Matteo, Racca, Patrizia, Mambrini, Andrea, Roselli, Mario, Allegrini, Giacomo, Sobrero, Alberto, Aglietta, Massimo, Corgna, Enrichetta, Cortesi, Enrico, Corsi, Domenico Cristiano, Ballestrero, Alberto, Bonetti, Andrea, Di Clemente, Francesco, Ruggeri, Enzo, Ciardiello, Fortunato, Benasso, Marco, Vitello, Stefano, Cinieri, Saverio, Mosconi, Stefania, Silvestris, Nicola, Frassoldati, Antonio, Cupini, Samantha, Bertolini, Alessandro, Tortora, Giampaolo, Bengala, Carmelo, Ferrari, Daris, Ardizzoia, Antonia, Milandri, Carlo, Chiara, Silvana, Romano, Gianpiero, Miraglia, Stefania, Scaltriti, Laura, Pucci, Francesca, Blasi, Livio, Brugnatelli, Silvia, Fioretto, Luisa, Ribecco, Angela Stefania, Longarini, Raffaella, Frisinghelli, Michela, Banzi, Maria, Cremolini, Chiara, Antoniotti, Carlotta, Rossini, Daniele, Loupakis, Fotios, Pietrantonio, Filippo, Latiano, Tiziana Pia, Passardi, Alessandro, Marmorino, Federica, Grande, Roberta, Murgioni, Sabina, Moretto, Roberto, Corallo, Salvatore, Cordio, Stefano, Antonuzzo, Lorenzo, Masi, Gianluca, Ronzoni, Monica, Ritorto, Giuliana, Cupini, Samanta, Mammoliti, Serafina, Fenocchio, Elisabetta, Zagonel, Vittorina, Fontanini, Gabriella, Ugolini, Clara, and Boni, Luca

Published
2020
Full Text
View/download PDF

16. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Author

Sangro, B., primary, Chan, S.L., additional, Kelley, R.K., additional, Lau, G., additional, Kudo, M., additional, Sukeepaisarnjaroen, W., additional, Yarchoan, M., additional, De Toni, E.N., additional, Furuse, J., additional, Kang, Y.K., additional, Galle, P.R., additional, Rimassa, L., additional, Heurgué, A., additional, Tam, V.C., additional, Van Dao, T., additional, Thungappa, S.C., additional, Breder, V., additional, Ostapenko, Y., additional, Reig, M., additional, Makowsky, M., additional, Paskow, M.J., additional, Gupta, C., additional, Kurland, J.F., additional, Negro, A., additional, Abou-Alfa, G.K., additional, Azevedo, Sergio, additional, Braghiroli, Maria Ignez, additional, Girotto, Gustavo, additional, Bragagnoli, Arinilda, additional, Branco, Ricardo, additional, Faccio, Adilson, additional, Moretto, Andrea, additional, Skare, Nils, additional, Dutra, Jamille, additional, Viola, Luciana, additional, Vianna, Karina, additional, Meton, Fernando, additional, Sette, Claudia, additional, Faulhaber, Amanda, additional, Tam, Vincent C., additional, Couture, Felix, additional, Biagi, Jim, additional, Castel, Helene, additional, Mulder, Karen, additional, Ko, Yoo-Joung, additional, Zbuk, Kevin, additional, Welch, Stephen, additional, Beaudoin, Annie, additional, Heurgué, Alexandra, additional, Assenat, Eric, additional, Archambeaud, Isabelle, additional, Tougeron, David, additional, Peron, Jean-Marie, additional, Gilabert, Marine, additional, Bronowicki, Jean-Pierre, additional, Cattan, Stephane, additional, Blanc, Jean-Frederic, additional, Bouattour, Mohamed, additional, Phelip, Jean-Marc, additional, Boige, Valerie, additional, Michel, Pierre, additional, Frin, Anne-Claire, additional, Enrico N De Toni, Germany, additional, Berres, Marie-Luise, additional, Vogel, Arndt, additional, Berg, Thomas, additional, Ettrich, Thomas, additional, Waldschmidt, Dirk, additional, Wedemeyer, Hans Heinrich, additional, Worns, Marcus-Alexander, additional, Bitzer, Michael, additional, Weiss, Karl-Heinz, additional, Lau, George, additional, Chan, Stephen L., additional, Yau, Thomas, additional, Tai, Yin Ping, additional, Lee, Ann Shing, additional, Thungappa, Satheesh Chiradoni, additional, N, Lokesh K., additional, Ostwal, Vikas Sureshchand, additional, Ashok, Kattimani Kiran, additional, Mittal, Sushant, additional, Goyal, Hari, additional, Srinivasan, Sankar, additional, Biswas, Ghanashyam, additional, Mohan, Mallavarapu, additional, Limaye, Sewanti, additional, Asarawala, Nirav, additional, Rimassa, Lorenza, additional, Falcone, Alfredo, additional, Gianni, Luca, additional, Gasbarrini, Antonio, additional, Daniele, Bruno, additional, Avallone, Antonio, additional, Paolo Frassineti, Giovanni Luca, additional, Roila, Fausto, additional, Kudo, Masatoshi, additional, Kawaoka, Tomokazu, additional, Morimoto, Manabu, additional, Takikawa, Yasuhiro, additional, Kato, Naoya, additional, Yamashita, Tatsuya, additional, Osaki, Yukio, additional, Motomura, Kenta, additional, Tateishi, Ryosuke, additional, Ohkawa, Kazuyoshi, additional, Wada, Yoshiyuki, additional, Onishi, Hideki, additional, Sasahira, Naoki, additional, Inaba, Yoshitaka, additional, Kurosaki, Masayuki, additional, Tsuji, Kunihiko, additional, Takei, Yoshiyuki, additional, Aramaki, Takeshi, additional, Hagihara, Atsushi, additional, Furuse, Junji, additional, Kioka, Kiyohide, additional, Koga, Hironori, additional, Sasaki, Yutaka, additional, Numata, Kazushi, additional, Tada, Toshifumi, additional, Kawaguchi, Yasunori, additional, Nadano, Seijin, additional, Alexander Vasilyev, Russian Federation, additional, Breder, Valery, additional, Lipatov, Oleg, additional, Dvorkin, Mikhail, additional, Zarubenkov, Oleg, additional, Kutukova, Svetlana, additional, Ponomarev, Roman, additional, Shostka, Kirill, additional, Alyasova, Anna, additional, Topuzov, Eldar, additional, Severtsev, Alexey, additional, Petrov, Yuryi, additional, Erygin, Dmitriy, additional, Berdov, Boris, additional, Kang, Yoon-Koo, additional, Tak, Won-Young, additional, Park, Joong-Won, additional, Lim, Ho Yeong, additional, Heo, Jeong, additional, Kim, Jee Hyun, additional, Kim, Tae-You, additional, Choi, Hye Jin, additional, Varela, María, additional, Reig Monzon, María Elisa, additional, Sangro, Bruno, additional, Martin, Carlos Gómez, additional, Ponce, Carmen Guillén, additional, López, Carlos, additional, Cheng, Ann-Lii, additional, Chao, Yee, additional, Feng, Yin-Hsun, additional, Jeng, Long-Bin, additional, Hung, Chao-Hung, additional, Hou, Ming-Mo, additional, Wang Tsang-En Wang, Jing-Houng, additional, Yen, Chia-Jui, additional, Sukeepaisarnjaroen, Wattana, additional, Sunpaweravong, Patrapim, additional, Charoentum, Chaiyut, additional, Tanasanvimon, Suebpong, additional, Sirachainan, Ekaphop, additional, Ungtrakul, Teerapat, additional, Prasongsook, Naiyarat, additional, Maneenil, Kunlatida, additional, Jitpewngarm, Wittawat, additional, Ostapenko, Yurii, additional, Skoryi, Denys, additional, Bondarenko, Igor, additional, Shparyk, Yaroslav, additional, Trukhin, Dmytro, additional, Hotko, Yevhen, additional, Ursol, Grygorii, additional, Kryzhanivska, Anna, additional, Abou-Alfa, Ghassan K., additional, Mody, Kabir, additional, Dayyani, Farshid, additional, Al-Rajabi, Raed, additional, Yarchoan, Mark, additional, Gandhi, Sunil, additional, Crysler, Oxana, additional, He, Aiwu Ruth, additional, Reeves, James, additional, Bahary, Nathan, additional, Mahipal, Amit, additional, Kelley, Robin Kate, additional, Dasgupta, Anirudha, additional, Rowe, Julie, additional, Thota, Ramya, additional, Beg, Muhammad, additional, Morse, Michael, additional, Choi, Sung-hee, additional, Crocenzi, Todd, additional, Somer, Bradley, additional, Abrams, Thomas, additional, Denlinger, Crystal, additional, Zhang, Yue, additional, Sharma, Nisha, additional, Dao, Tu V., additional, Thinh, Nguyen Tien, additional, and Tuyet Phuong, Le Thi, additional

Published
2024
Full Text
View/download PDF

17. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer

Author

Rapposelli, Ilario Giovanni, Zampiga, Valentina, Cangini, Ilaria, Arcangeli, Valentina, Ravegnani, Mila, Valgiusti, Martina, Pini, Sara, Tamberi, Stefano, Bartolini, Giulia, Passardi, Alessandro, Martinelli, Giovanni, Calistri, Daniele, Frassineti, Giovanni Luca, Falcini, Fabio, and Danesi, Rita

Published
2021
Full Text
View/download PDF

19. Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer

Author

Monti, Manlio, primary, Prochowski Iamurri, Andrea, additional, Bianchini, David, additional, Gallio, Chiara, additional, Esposito, Luca, additional, Montanari, Daniela, additional, Ruscelli, Silvia, additional, Molinari, Chiara, additional, Foca, Flavia, additional, Passardi, Alessandro, additional, Vittimberga, Giovanni, additional, Morgagni, Paolo, additional, and Frassineti, Giovanni Luca, additional

Published
2023
Full Text
View/download PDF

20. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale

Author

Casadei Gardini, Andrea, Faloppi, Luca, De Matteis, Serena, Foschi, Francesco Giuseppe, Silvestris, Nicola, Tovoli, Francesco, Palmieri, Vincenzo, Marisi, Giorgia, Brunetti, Oronzo, Vespasiani-Gentilucci, Umberto, Perrone, Giuseppe, Valgiusti, Martina, Granato, Anna Maria, Ercolani, Giorgio, Negrini, Giulia, Tamburini, Emiliano, Aprile, Giuseppe, Passardi, Alessandro, Santini, Daniele, Cascinu, Stefano, Frassineti, Giovanni Luca, and Scartozzi, Mario

Published
2017
Full Text
View/download PDF

21. Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Author

Bang, Yeonghak, Yoo, Changhoon, Lonardi, Sara, Kim, Hyung-Don, Vivaldi, Caterina, Rimini, Margherita, Frassineti, Giovanni Luca, Park, Sook Ryun, Rizzato, Mario Domenico, Ryu, Min-Hee, Salani, Francesca, Rapposelli, Ilario Giovanni, Ryoo, Baek-Yeol, Zagonel, Vittorina, Massa, Valentina, Valgiusti, Martina, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2021
Full Text
View/download PDF

22. Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.

Author

Passardi, Alessandro, Azzali, Irene, Bittoni, Alessandro, Marisi, Giorgia, Rebuzzi, Francesca, Molinari, Chiara, Bartolini, Giulia, Matteucci, Laura, Sullo, Francesco Giulio, Debonis, Silvia Angela, Gallio, Chiara, Monti, Manlio, Valgiusti, Martina, Muratore, Margherita, Rapposelli, Ilario Giovanni, Ulivi, Paola, and Frassineti, Giovanni Luca

Abstract

Background: Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported to be useful prognostic factors in various malignant solid tumours, including metastatic colorectal cancer (mCRC). Objectives: To explore the prognostic value of IIs in mCRC patients treated with first-line chemotherapy plus Bev. Design: One hundred and eighty-two patients diagnosed with mCRC and treated with first line chemotherapy plus Bev were considered for this prospective non-pharmacological study. Neutrophil, lymphocyte, platelet, aspartate transaminase (AST) and lactate dehydrogenase (LDH) tests were carried out at baseline and before each treatment cycle, according to clinical practice. Methods: Pre-treatment Systemic Immune-inflammation Index (SII), Colon Inflammatory Index (CII) and Aspartate aminotransferase-Lymphocyte Ratio Index (ALRI) were evaluated to assess a correlation with progression-free survival (PFS) and overall survival (OS). Results: In the overall population, PFS and OS were lower in patients with high SII (HR 1.64, p = 0.006 and HR 1.75, p = 0.004, respectively) and high ALRI (HR 2.13, p = 0.001 and HR 1.76, p = 0.02, respectively), but no difference was detected according to CII value. The multivariate analysis confirmed both SII and ALRI as independent prognostic factors for PFS (HR 1.64 and 2.82, respectively) and OS (HR 1.65 and 2.12, respectively). Conclusion: Our results demonstrate and confirm that IIs, and in particular SII and ALRI, are easy to measure prognostic markers for patient candidates to first line chemotherapy plus Bev for mCRC. Plain language summary: Inflammatory Indexes can predict the efficacy of bevacizumab in metastatic colorectal cancer Bevacizumab (Bev) is a humanized monoclonal antibody with antiangiogenic activity, used in combination with chemotherapy as a standard first line treatment for many metastatic colorectal cancer patients. Validated predictors of sensitivity or resistance to Bevacizumab are not available, although several studies have investigated this issue in recent years. In this study, we investigated whether some selected baseline inflammatory indexes levels, namely Systemic Immune-inflammation Index (SII) and Aspartate aminotransferase-Lymphocyte Ratio Index (ALRI) could predict the survival in patients with metastatic colorectal cancer treated with Bevacizumab plus chemotherapy. We enrolled 182 patients diagnosed with mCRC and treated with first line chemotherapy plus Bev. For each patient we tested blood neutrophils, lymphocytes, platelets, aspartate transaminase (AST) and lactate dehydrogenase (LDH) before each treatment cycle, according to clinical practice. We calculated the SII value as platelet count × neutrophil count/lymphocyte count, and ALRI as AST/lymphocyte count. We found that patients with high SII and high ALRI values had lower survival as compared to those with low values. These parameters represent reproducible, inexpensive and easy to measure biomarkers to be used in both clinical practice and clinical trials, for patient selection. Visual Abstract [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.

Author

Lonardi, Sara, Rasola, Cosimo, Lobefaro, Riccardo, Rossini, Daniele, Formica, Vincenzo, Scartozzi, Mario, Frassineti, Giovanni Luca, Boscolo, Giorgia, Cinieri, Saverio, Di Donato, Samantha, Pella, Nicoletta, Bergamo, Francesca, Raimondi, Alessandra, Arnoldi, Ermenegildo, Antonuzzo, Lorenzo, Granetto, Cristina, Zustovich, Fable, Ronzoni, Monica, Leo, Silvana, and Morano, Federica

Published
2023
Full Text
View/download PDF

24. Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life

Author

Farolfi, Alberto, Ruscelli, Silvia, Valgiusti, Martina, Pini, Sara, Faedi, Marina, Ragazzini, Angela, Pittureri, Cristina, Amaducci, Elena, Guglieri, Irene, Bergamo, Francesca, Lonardi, Sara, Di Nunzio, Camilla, Bosco, Monica, Bocci, Barbara, Bramanti, Alfina, Gandini, Chiara, Buonadonna, Angela, Comandone, Alessandro, Zoccali, Sonia, Pino, Maria Simona, Dalu, Davide, Sozzi, Pietro, Gozza, Alberto, Giordano, Monica, Longhi, Carla, Autelitano, Cristina, Gamucci, Teresa, Mastromauro, Cataldo, Scognamiglio, Rodolfo, Degiovanni, Daniela, Negri, Federica, Caraceni, Augusto, Montanari, Luigi, Maltoni, Marco, Scarpi, Emanuela, Dall’Agata, Monia, Schiavon, Stefania, Biasini, Claudia, Codecà, Carla, Broglia, Chiara Maria, Sansoni, Elisabetta, Bortolussi, Roberto, Garetto, Ferdinando, Fioretto, Luisa, Cattaneo, Maria Teresa, Giacobino, Alice, Luzzani, Massimo, Luchena, Giovanna, Alquati, Sara, Quadrini, Silvia, Zagonel, Vittorina, Cavanna, Luigi, Ferrari, Daris, Pedrazzoli, Paolo, Frassineti, Giovanni Luca, Galiano, Antonella, Casadei Gardini, Andrea, Monti, Manlio, and Nanni, Oriana

Published
2016
Full Text
View/download PDF

26. Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer

Author

Marisi, Giorgia, primary, Azzali, Irene, additional, passardi, alessandro, additional, Rebuzzi, Francesca, additional, Bartolini, Giulia, additional, Urbini, Milena, additional, Canale, Matteo, additional, Molinari, Chiara, additional, Matteucci, Laura, additional, Sullo, Francesco, additional, Debonis, Silvia Angela, additional, Gallio, Chiara, additional, Gallo, Graziana, additional, Frassineti, Giovanni Luca, additional, and Ulivi, Paola, additional

Published
2023
Full Text
View/download PDF

27. Analysis of extracellular vesicles from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value

Author

Vannini, Ivan, primary, Rossi, Tania, additional, Melloni, Mattia, additional, Valgiusti, Martina, additional, Urbini, Milena, additional, Passardi, Alessandro, additional, Bartolini, Giulia, additional, Gallio, Chiara, additional, Azzali, Irene, additional, Bandini, Sara, additional, Ancarani, Valentina, additional, Montanaro, Lorenzo, additional, Frassineti, Giovanni Luca, additional, Fabbri, Francesco, additional, and Rapposelli, Ilario Giovanni, additional

Published
2023
Full Text
View/download PDF

28. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Author

Tempero, Margaret A., primary, Pelzer, Uwe, additional, O'Reilly, Eileen M., additional, Winter, Jordan, additional, Oh, Do-Youn, additional, Li, Chung-Pin, additional, Tortora, Giampaolo, additional, Chang, Heung-Moon, additional, Lopez, Charles D., additional, Bekaii-Saab, Tanios, additional, Ko, Andrew H., additional, Santoro, Armando, additional, Park, Joon Oh, additional, Noel, Marcus S., additional, Frassineti, Giovanni Luca, additional, Shan, Yan-Shen, additional, Dean, Andrew, additional, Riess, Hanno, additional, Van Cutsem, Eric, additional, Berlin, Jordan, additional, Philip, Philip, additional, Moore, Malcolm, additional, Goldstein, David, additional, Tabernero, Josep, additional, Li, Mingyu, additional, Ferrara, Stefano, additional, Le Bruchec, Yvan, additional, Zhang, George, additional, Lu, Brian, additional, Biankin, Andrew V., additional, Reni, Michele, additional, Epstein, Richard, additional, Vasey, Paul, additional, Shapiro, Jeremy, additional, Burge, Matthew, additional, Chua, Yu Jo, additional, Harris, Marion, additional, Pavlakis, Nick, additional, Tebbutt, Niall, additional, Prager, Gerald, additional, Dittrich, Christian, additional, Längle, Friedrich, additional, Philipp-Abbrederis, Kathrin, additional, Greil, Richard, additional, Stöger, Herbert, additional, Girschikofsky, Michael, additional, Kuehr, Thomas, additional, Van Laethem, Jean-Luc, additional, Laurent, Stéphanie, additional, Dhani, Neesha, additional, Ko, Yoo Joung, additional, Dowden, Scot, additional, Kavan, Petr, additional, Tehfe, Mustapha Édouard, additional, Kubala, Eugen, additional, Kohoutek, Milan, additional, Pfeiffer, Per, additional, Yilmaz, Mette, additional, Parner, Vibeke, additional, Salminen, Tapio, additional, Soveri, Leena-Maija, additional, Korkeila, Eija, additional, Osterlund, Pia, additional, Taieb, Julien, additional, Tougeron, David, additional, Artru, Pascal, additional, Caroli-Bosc, François Xavier, additional, Guimbaud, Rosine, additional, Turpin, Antony, additional, Walter, Thomas, additional, Bachet, Jean Baptiste, additional, Kunzmann, Volker, additional, Kreth, Florian, additional, Block, Andreas, additional, Venerito, Marino, additional, Oettle, Helmut, additional, Karthaus, Meinolf, additional, Trojan, Jörg, additional, Folprecht, Gunnar, additional, Lerch, Markus, additional, Kullmann, Frank, additional, Reiser, Marcel, additional, Heinemann, Volker, additional, Wörns, Marcus-Alexander, additional, Schulz, Holger, additional, Garlipp, Benjamin, additional, Yau, Thomas, additional, Chan, Lam Stephen, additional, Juhasz, Balazs, additional, Landherr, László, additional, Pinter, Tamas, additional, Bodoky, György, additional, Kahán, Zsuzsanna, additional, McDermott, Raymond, additional, Power, Derek, additional, Gianni, Luca, additional, Siena, Salvatore, additional, Milella, Michele, additional, Falcone, Alfredo, additional, Berardi, Rossana, additional, Bagalà, Cinzia, additional, Di Costanzo, Francesco, additional, Roila, Fausto, additional, Ardizzoni, Andrea, additional, Maiello, Evaristo, additional, Fanello, Silvia, additional, Wilmink, Johanna, additional, Willem de Groot, Jan, additional, Creemers, Geert, additional, Barroso, Eduardo, additional, Rodrigues, Tânia, additional, Sarmento, Cristina, additional, Chee, Cheng Ean, additional, Tai, David, additional, Mercade, Teresa Macarulla, additional, Medina, Manuel Hidalgo, additional, Mena, Alfredo Carrato, additional, Santasusana, Joan Maurel, additional, Flor Oncala, Maria Jose, additional, Martin, Carlos Gomez, additional, Lopez, Rafael, additional, Muñoz, Andres, additional, Garcia, Ruth Vera, additional, Ales, Inmaculada, additional, Sáez, Berta Laquente, additional, Rivera, Fernando, additional, Sastre, Javier, additional, Wu, Cheng-Chung, additional, Tien, Yu-Wen, additional, Chan, De-Chuan, additional, Hwang, Tsann-Long, additional, Evans, Jeffry, additional, Wadsley, Jonathan, additional, Corrie, Pippa, additional, Biankin, Andrew, additional, Ko, Andrew, additional, Cardin, Dana, additional, Chiorean, Elena, additional, Bendell, Johanna, additional, Noonan, Anne, additional, Kindler, Hedy, additional, Fernando, Nishan, additional, Beg, Muhammad, additional, George, Thomas, additional, Noel, Marcus, additional, LoConte, Noelle, additional, Arena, Francis, additional, Posey, James, additional, Malhotra, Rajat, additional, Lopez, Charles, additional, Sohal, Davendra, additional, McWilliams, Robert, additional, Brenner, Warren, additional, Womack, Mark, additional, Seth, Rahul, additional, lyer, Renuka, additional, Bahary, Nathan, additional, Marsh, Robert, additional, Ramirez, Robert, additional, Chua, Cynthia, additional, Reeves, James, additional, Manji, Gulam, additional, El-Khoueiry, Anthony, additional, Weaver, Robert, additional, Sahai, Vaibhav, additional, Messersmith, Wells, additional, Dreicer, Robert, additional, Zakari, Ahmed, additional, Bullock, Andrea, additional, Musher, Benjamin, additional, Borad, Mitesh, additional, Kim, Edward, additional, Bajor, David, additional, Huyck, Tim, additional, Hatoum, Hassan, additional, Xiong, Henry, additional, Pasche, Boris, additional, Lacy, Jill, additional, Olowokure, Olugbenga, additional, Cohn, Allen, additional, Richards, Donald, additional, Martin, Robert, additional, Paulson, Andrew, additional, Fanta, Paul, additional, Krishnamurthi, Smitha, additional, Oberstein, Paul, additional, and Fuloria, Jyotsna, additional

Published
2023
Full Text
View/download PDF

29. Prevalence of a BRCA2 Pathogenic Variant in Hereditary-Breast-and-Ovarian-Cancer-Syndrome Families with Increased Risk of Pancreatic Cancer in a Restricted Italian Area

Author

Zampiga, Valentina, primary, Cangini, Ilaria, additional, Bandini, Erika, additional, Azzali, Irene, additional, Ravegnani, Mila, additional, Ravaioli, Alessandra, additional, Mancini, Silvia, additional, Tebaldi, Michela, additional, Tedaldi, Gianluca, additional, Pirini, Francesca, additional, Veneroni, Luigi, additional, Frassineti, Giovanni Luca, additional, Falcini, Fabio, additional, Danesi, Rita, additional, Calistri, Daniele, additional, and Arcangeli, Valentina, additional

Published
2023
Full Text
View/download PDF

30. Ruolo delle tecniche di sequenziamento di ultima generazione nella gestione dei pazienti con carcinoma colorettale metastatico

Author

Frassineti, Giovanni Luca Paolo, Matteucci, Laura <1983>, Frassineti, Giovanni Luca Paolo, and Matteucci, Laura <1983>

Abstract

L'utilità clinica dell’uso routinario delle tecniche di sequenziamento di nuova generazione (NGS) nei pazienti con cancro colorettale metastatico andrebbe approfondita. In questo studio, è stato valutato l'impatto di un pannello NGS da 52 geni utilizzato nella pratica clinica di routine. Abbiamo analizzato i risultati dei test molecolari multigenici in pazienti con carcinoma colorettale metastatico (mCRC) in uno studio osservazionale, retrospettivo e monocentrico su pazienti affetti da carcinoma colorettale metastatico consecutivamente testati presso un centro oncologico italiano tra giugno 2019 e dicembre 2020. Le analisi di sopravvivenza sono state effettuate con il metodo Kaplan-Meier, test log-rank e modello di Cox. Complessivamente sono stati inclusi 179 pazienti con mCRC. Il follow-up mediano è stato di 33 mesi (IQR: 28,45–NR). I quattro geni più frequentemente mutati sono stati: KRAS (48,6%), PIK3CA (22,4%), BRAF (14,5%) e APC (8,4%). È stata trovata un'associazione positiva tra la sopravvivenza globale (OS) e le mutazioni KRAS con un'alta frequenza allelica variante (VAF) [HR: 0,60 (0.36 – 0.99), P=0.047]. La mutazione BRAF era associata a OS inferiore [HR: 2,62 (1,59-4,32), P <0,001]. Il panello NGS ha consentito a otto pazienti di accedere a terapie a bersaglio molecolare non ancora registrate per il cancro colorettale. In conclusione, i pannelli NGS in mCRC sono fattibili nella pratica clinica in laboratori di riferimento per consentire un impatto inferiore sui costi e un aggiornamento regolare. La mutazione di BRAF risulta associata a una prognosi peggiore. Le mutazioni di KRAS con un’elevata variazione di frequenza allelica erano associate a una sopravvivenza globale superiore rispetto ai pazienti KRAS non mutati. Sono necessari studi più approfonditi per analizzare meglio i fattori prognostici., The clinical impact of targeted next-generation sequencing (NGS) in routine practice should be addressed in metastatic colorectal cancers. In this work, we studied the impact of a 52-gene amplicon-based NGS panel performed in routine practice. We analyzed the results of multigene molecular testing in metastatic colorectal cancer (mCRC) patients in a single-center, retrospective, observational study of consecutive mCRC patients tested at an Italian cancer centre between June 2019 and December 2020. Outcome was evaluated by the Kaplan–Meier method, log-rank tests and Cox models. Overall, 179 patients with mCRC were included. Median follow-up was 33 months (IQR: 28.45–NR). The four most frequently mutated genes were: KRAS (48.6%), PIK3CA (22.4%), BRAF (14.5%) and APC (8.4%). A positive association was found between overall survival and KRAS mutations with a high variant allele frequency (VAF) [HR: 0,60 (0.36 – 0.99), P=0.047]. BRAF mutation was associated with inferior overall survival (OS) [HR: 2.62 (1.59–4.32), P < 0.001]. The NGS panel enabled eight patients to access a targeted therapy not currently registered for mCRC. In conclusion, NGS panels in mCRC are feasible in reference laboratories for routine practice to allow for lower cost impact and regular updating. BRAF mutation is associated with a worse prognosis. Mutations in KRAS with a high VAF were associated with superior OS of mCRC patients compared with patients with KRAS wild-type tumors. In-depth studies are needed to better analyze the prognostic factors.

Published
2023

31. Association between pre-treatment indicators and compliance to neoadjuvant/perioperative chemotherapy in operable gastric cancer

Author

Frassineti, Giovanni Luca Paolo, Monti, Manlio <1973>, Frassineti, Giovanni Luca Paolo, and Monti, Manlio <1973>

Abstract

Background and aims: perioperative treatment is currently the gold standard approach for locally advanced gastric cancer (GC). Unfortunately, the phenomenon of patients dropping out of treatment has been frequently observed. The primary aims of this study were to verify if routine blood parameters, the inflammatory response markers, sarcopenia, and the depletion of adipose tissues were associated with compliance with neoadjuvant/perioperative chemotherapy. Methods and study design: sarcopenia and adipose indices were calculated with a CT scan before starting chemotherapy and before surgery. Blood samples were considered before the first and second cycles of chemotherapy. Results: A total of 84 patients with localized operable GC, were identified between September 2010 and January 2021. Forty-four patients (52.4%) did not complete the treatment according to the number of cycles planned/performed. Eight patients (9.5%) decided to suspend chemotherapy, seven patients (8.3%) discontinued because of clinical decision-making, 14 patients (16.7%) because of toxicity, and 15 patients (17.9%) for miscellaneous causes. Sarcopenia before starting chemotherapy was found to be present in 38 patients (50.7%) while it was in 47 patients (60%) at the CT scan before the gastrectomy. In multivariable analysis, both for changes tending to have a value of PLR at basal and in the second control a higher one than the cut-off (OR = 5.03, 95% CI: 1.34 - 18.89, p-value = 0.017), and for PLR which increased from a lower to a higher value in second control with respect to the cut off (OR = 4.64, 95% CI: 1.02 -21.02, p-value = 0.047) resulted associated with incomplete compliance. Conclusions: among the biological indicators, changes in the value of PLR with a tendency towards increasing compared to the cut-off appear to be an immediate indicator of incomplete compliance with neoadjuvant/perioperative treatment. More information is needed to reduce the causes of interruption.

Published
2023

32. Analysis of extracellular vesicles from patients with advanced pancreatic cancer identifies miRNAs with predictive value for treatment with gemcitabine + nab-paclitaxel

Author

Frassineti, Giovanni Luca Paolo, Rapposelli, Ilario Giovanni <1983>, Frassineti, Giovanni Luca Paolo, and Rapposelli, Ilario Giovanni <1983>

Abstract

Pancreatic cancer (PC) is the seventh leading cause of cancer death. Despite recent therapy advancements, 5-year survival is 11%. Resistance to therapy is common, and no predictive factors, except for BRCA1/2 and PALB2 mutations, can drive treatment selection. Based on the easy isolation of extracellular vesicles (EVs) from blood and the role of EV-borne miRNAs in chemoresistance, we analyzed EVs and their miRNA content in order to identify predictive factors. First, we analyzed samples from 28 PC patients and 7 healthy subjects, in order to establish methods for isolation and analysis of EVs and their miRNA content. We observed a significantly different expression of 28 miRNAs, including oncogenic or tumor suppressor miRNAs, showing the ability of our approach to detect candidate biomarkers. Then, we analyzed samples of 21 advanced PC patients, collected before first-line treatment with gemcitabine + nab-paclitaxel, and compared findings in responders and non-responders. EVs have been analyzed with Nanoparticle tracking analysis, flow cytometry and RNA-Seq; then, laboratory results have been matched with clinical data. Nanoparticle tracking analysis did not show any significant difference. Flow cytometry showed a lower expression of SSE4 and CD81 in responders. Finally, miRNA analysis showed 25 upregulated and 19 downregulated miRNAs in responders. In particular, in responders we observed upregulation of miR-141-3p, miR-141-5p, miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-375-3p, miR-429, miR-545-5p. These miRNAs have targets with a previously reported role in PC. In conclusion, we show the feasibility of the proposed approach to identify EV-derived biomarkers with predictive value for therapy with gemcitabine + nab-paclitaxel in PC. Our findings highlight the possibility to exploit liquid biopsy for personalized treatment in PC, in order to maximize chances of response and patients’ outcome. These findings are worthy of further investigation: in the same setting, wi

Published
2023

33. Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial

Author

Frassineti, Giovanni Luca, Sansoni, Elisabetta, Ragazzini, Angela, Ruscelli, Silvia, Crivellari, Gino, Galiano, Antonella, Rodriquenz, Maria Grazia, Biasini, Claudia, Porzio, Rosa, Pittureri, Cristina, Amaducci, Elena, Faedi, Marina, Codecà, Carla, Crepaldi, Francesca, Pedrazzoli, Paolo, Bramanti, Alfina, Buonadonna, Angela, Garetto, Ferdinando, Comandone, Alessandro, Giordano, Monica, Luchena, Giovanna, Luzzani, Massimo, Cifatte, Chiara, Pino, Maria Simona, Zoccali, Sonia, Cattaneo, Maria Teresa, Dalu, Davide, Sozzi, Pietro, Gauna, Roberta, Alquati, Sara, Costantini, Massimo, Quadrini, Silvia, Narducci, Filomena, Mastromauro, Cataldo, Scognamiglio, Rodolfo, Degiovanni, Daniela, Negri, Federica, Caraceni, Augusto, Montanari, Luigi, Maltoni, Marco, Scarpi, Emanuela, Dall'Agata, Monia, Zagonel, Vittorina, Bertè, Raffaella, Ferrari, Daris, Broglia, Chiara Maria, Bortolussi, Roberto, Trentin, Leonardo, Valgiusti, Martina, Pini, Sara, Farolfi, Alberto, Casadei Gardini, Andrea, Nanni, Oriana, and Amadori, Dino

Published
2016
Full Text
View/download PDF

34. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

Author

Di Bartolomeo, Maria, Niger, Monica, Morano, Federica, Corallo, Salvatore, Antista, Maria, Tamberi, Stefano, Lonardi, Sara, Di Donato, Samantha, Berardi, Rossana, Scartozzi, Mario, Cardellino, Giovanni Gerardo, Di Costanzo, Francesco, Rimassa, Lorenza, Luporini, Alberto Gianluigi, Longarini, Raffaella, Zaniboni, Alberto, Bertolini, Alessandro, Tomasello, Gianluca, Pinotti, Graziella, Scagliotti, Giorgio, Tortora, Giampaolo, Bonetti, Andrea, Spallanzani, Andrea, Frassineti, Giovanni Luca, Tassinari, Davide, Giuliani, Francesco, Cinieri, Saverio, Maiello, Evaristo, Verusio, Claudio, Bracarda, Sergio, Catalano, Vincenzo, Basso, Michele, Ciuffreda, Libero, De Vita, Ferdinando, Parra, Hector Soto, Fornaro, Lorenzo, Caporale, Marta, de Braud, Filippo, and Pietrantonio, Filippo

Published
2019
Full Text
View/download PDF

37. Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin

Author

Fausti, Valentina, primary, De Vita, Alessandro, additional, Vanni, Silvia, additional, Ghini, Virginia, additional, Gurrieri, Lorena, additional, Riva, Nada, additional, Casadei, Roberto, additional, Maraldi, Marco, additional, Ercolani, Giorgio, additional, Cavaliere, Davide, additional, Pacilio, Carlo Alberto, additional, Pieri, Federica, additional, Foca, Flavia, additional, Bongiovanni, Alberto, additional, Ranallo, Nicoletta, additional, Calpona, Sebastiano, additional, Frassineti, Giovanni Luca, additional, Ibrahim, Toni, additional, and Mercatali, Laura, additional

Published
2023
Full Text
View/download PDF

38. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

Author

Yau, Thomas, primary, Zagonel, Vittorina, additional, Santoro, Armando, additional, Acosta-Rivera, Mirelis, additional, Choo, Su Pin, additional, Matilla, Ana, additional, He, Aiwu Ruth, additional, Cubillo Gracian, Antonio, additional, El-Khoueiry, Anthony B., additional, Sangro, Bruno, additional, Eldawy, Tarek E., additional, Bruix, Jordi, additional, Frassineti, Giovanni Luca, additional, Vaccaro, Gina M., additional, Tschaika, Marina, additional, Scheffold, Christian, additional, Koopmans, Petra, additional, Neely, Jaclyn, additional, and Piscaglia, Fabio, additional

Published
2022
Full Text
View/download PDF

40. Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry

Author

Pedrazzoli, Paolo, Martinelli, Giovanni, Gianni, Alessandro Massimo, Da Prada, Gian Antonio, Ballestrero, Alberto, Rosti, Giovanni, Frassineti, Giovanni Luca, Aieta, Michele, Secondino, Simona, Cinieri, Saverio, Fedele, Roberta, Bengala, Carmelo, Bregni, Marco, Grasso, Donatella, De Giorgi, Ugo, Lanza, Francesco, Castagna, Luca, Bruno, Barbara, and Martino, Massimo

Published
2014
Full Text
View/download PDF

43. Platinum sensitivity in patients with IDH1/2 mutated vs wild‐type intrahepatic cholangiocarcinoma: A propensity score‐based study

Author

Niger, Monica, primary, Nichetti, Federico, additional, Casadei‐Gardini, Andrea, additional, Rizzato, Mario Domenico, additional, Pircher, Chiara, additional, Bini, Marta, additional, Franza, Andrea, additional, Rimini, Margherita, additional, Burgio, Valentina, additional, Sposetti, Caterina, additional, Fornaro, Lorenzo, additional, Rapposelli, Ilario Giovanni, additional, D'Amico, Francesco Enrico, additional, Aprile, Giuseppe, additional, Vivaldi, Caterina, additional, Frassineti, Giovanni Luca, additional, Milione, Massimo, additional, Leoncini, Giuseppe, additional, Cappetta, Alessandro, additional, Vasile, Enrico, additional, Fassan, Matteo, additional, Morano, Federica, additional, Perrone, Federica, additional, Tamborini, Elena, additional, Pruneri, Giancarlo, additional, Lonardi, Sara, additional, Mazzaferro, Vincenzo, additional, Pietrantonio, Filippo, additional, Di Bartolomeo, Maria, additional, and de Braud, Filippo, additional

Published
2022
Full Text
View/download PDF

44. The genomic landscape of IDH1 mutant intrahepatic cholangiocarcinoma: a multicentre comprehensive analysis

Author

Rimini, Margherita, primary, Macarulla, Teresa Mercade, additional, Burgio, Valentina, additional, Lonardi, Sara, additional, Niger, Monica, additional, Scartozzi, Mario, additional, Raposelli, Ilario, additional, Aprile, Giuseppe, additional, Ratti, Francesca, additional, Pedica, Federica, additional, Verdaguer, Helena, additional, Nappo, Floriana, additional, Nichetti, Federico, additional, Lai, Eleonora, additional, Valgiusti, Martina, additional, Cappetta, Alessandro, additional, Fabregat, Carles, additional, Fassan, Matteo, additional, De Braud, Filippo, additional, Puzzoni, Marco, additional, Frassineti, Giovanni Luca, additional, Simionato, Francesca, additional, De Cobelli, Francesco, additional, Aldrighetti, Luca, additional, Fornaro, Lorenzo, additional, Cascinu, Stefano, additional, and Gardini, Andrea Casadei, additional

Published
2022
Full Text
View/download PDF

45. Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis

Author

Ranallo, Nicoletta, primary, Iamurri, Andrea Prochoswski, additional, Foca, Flavia, additional, Liverani, Chiara, additional, De Vita, Alessandro, additional, Mercatali, Laura, additional, Calabrese, Chiara, additional, Spadazzi, Chiara, additional, Fabbri, Carlo, additional, Cavaliere, Davide, additional, Galassi, Riccardo, additional, Severi, Stefano, additional, Sansovini, Maddalena, additional, Tartaglia, Andreas, additional, Pieri, Federica, additional, Crudi, Laura, additional, Bianchini, David, additional, Barone, Domenico, additional, Martinelli, Giovanni, additional, Frassineti, Giovanni Luca, additional, Ibrahim, Toni, additional, Calabrò, Luana, additional, Berardi, Rossana, additional, and Bongiovanni, Alberto, additional

Published
2022
Full Text
View/download PDF

46. A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results.

Author

Tamberi, Stefano, primary, Grassi, Elisa, additional, Zingaretti, Chiara, additional, Papiani, Giorgio, additional, Pini, Sara, additional, Corbelli, Jody, additional, Di Bartolomeo, Maria, additional, Pietrantonio, Filippo, additional, Frassineti, Giovanni Luca, additional, Passardi, Alessandro, additional, Gelsomino, Fabio, additional, Marzola, Marina, additional, Banzi, Maria, additional, Bonetti, Andrea Vincent, additional, Petracci, Elisabetta, additional, Carli Moretti, Chiara, additional, Banchelli, Isabella, additional, Tassinari, Davide, additional, Ugolini, Giampaolo, additional, and Nanni, Oriana, additional

Published
2022
Full Text
View/download PDF

47. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial

Author

Tempero, Margaret A., Pelzer, Uwe, O'Reilly, Eileen M., Winter, Jordan, Oh, Do-Youn, Li, Chung-Pin, Tortora, Giampaolo, Chang, Heung-Moon, Lopez, Charles D., Bekaii-Saab, Tanios, Ko, Andrew H., Santoro, Armando, Park, Joon Oh, Noel, Marcus S., Frassineti, Giovanni Luca, Shan, Yan-Shen, Dean, Andrew, Riess, Hanno, Van Cutsem, Eric, Berlin, Jordan, Philip, Philip, Moore, Malcolm, Goldstein, David, Tabernero, Josep, Li, Mingyu, Ferrara, Stefano, Le Bruchec, Yvan, Zhang, George, Lu, Brian, Biankin, Andrew V., Reni, Michele, Tempero, Margaret A., Pelzer, Uwe, O'Reilly, Eileen M., Winter, Jordan, Oh, Do-Youn, Li, Chung-Pin, Tortora, Giampaolo, Chang, Heung-Moon, Lopez, Charles D., Bekaii-Saab, Tanios, Ko, Andrew H., Santoro, Armando, Park, Joon Oh, Noel, Marcus S., Frassineti, Giovanni Luca, Shan, Yan-Shen, Dean, Andrew, Riess, Hanno, Van Cutsem, Eric, Berlin, Jordan, Philip, Philip, Moore, Malcolm, Goldstein, David, Tabernero, Josep, Li, Mingyu, Ferrara, Stefano, Le Bruchec, Yvan, Zhang, George, Lu, Brian, Biankin, Andrew V., and Reni, Michele

Abstract

PURPOSE This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430). METHODS We assigned 866 treatment-naive patients with pancreatic ductal adenocarcinoma to nab-paclitaxel (125 mg/m2) + gemcitabine (1,000 mg/m2) or gemcitabine alone to one 30-40 infusion on days 1, 8, and 15 of six 28-day cycles. The primary end point was independently assessed disease-free survival (DFS). Additional end points included investigator-assessed DFS, overall survival (OS), and safety. RESULTS Two hundred eighty-seven of 432 patients and 310 of 434 patients completed nab-paclitaxel + gemcitabine and gemcitabine treatment, respectively. At primary data cutoff (December 31, 2018; median follow-up, 38.5 [interquartile range [IQR], 33.8-43 months), the median independently assessed DFS was 19.4 (nab-paclitaxel + gemcitabine) versus 18.8 months (gemcitabine; hazard ratio [HR], 0.88; 95% CI, 0.729 to 1.063; P = .18). The median investigator-assessed DFS was 16.6 (IQR, 8.4-47.0) and 13.7 (IQR, 8.3-44.1) months, respectively (HR, 0.82; 95% CI, 0.694 to 0.965; P = .02). The median OS (427 events; 68% mature) was 40.5 (IQR, 20.7 to not reached) and 36.2 (IQR, 17.7-53.3) months, respectively (HR, 0.82; 95% CI, 0.680 to 0.996; P = .045). At a 16-month follow-up (cutoff, April 3, 2020; median follow-up, 51.4 months [IQR, 47.0-57.0]), the median OS (511 events; 81% mature) was 41.8 (nab-paclitaxel + gemcitabine) versus 37.7 months (gemcitabine; HR, 0.82; 95% CI, 0.687 to 0.973; P = .0232). At the 5-year follow-up (cutoff, April 9, 2021; median follow-up, 63.2 months [IQR, 60.1-68.7]), the median OS (555 events; 88% mature) was 41.8 versus 37.7 months, respectively (HR, 0.80; 95% CI, 0.678 to 0.947; P = .0091). Eighty-six percent (nab-paclitaxel + gemcitabine) and 68% (gemcitabine) of patients experienced grade ≥ 3 treatment-emergent adve

Published
2022

48. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.

Author

Yau, Thomas, Zagonel, Vittorina, Santoro, Armando, Acosta-Rivera, Mirelis, Choo, Su Pin, Matilla, Ana, He, Aiwu Ruth, Cubillo Gracian, Antonio, El-Khoueiry, Anthony B., Sangro, Bruno, Eldawy, Tarek E., Bruix, Jordi, Frassineti, Giovanni Luca, Vaccaro, Gina M., Tschaika, Marina, Scheffold, Christian, Koopmans, Petra, Neely, Jaclyn, and Piscaglia, Fabio

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results